MedTrace Logo

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

NCT00220779 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2016-04-27

Study results available
· View outcomes & findings →

Summary

The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified

DRUG

Albumin (Human) 25%, United States Pharmacopeia (USP)

Sponsors & Collaborators

  • Grifols Therapeutics LLC

    lead INDUSTRY

Principal Investigators

  • Fred D Lublin, MD · Mt Sinai Medical Center, New York, NY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2005-02-28
Completion
2005-02-28

Countries

  • United States
  • Austria
  • Canada
  • Czechia
  • Germany
  • Greece
  • Hungary
  • Israel
  • Poland
  • Slovakia
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00220779 on ClinicalTrials.gov